Perjeta 420mg Injection
Perjeta 420mg Injection (Pertuzumab) is a targeted monoclonal antibody therapy used for the treatment of HER2-positive metastatic breast cancer. It is commonly prescribed in combination with trastuzumab (Herceptin) and chemotherapy to inhibit cancer cell growth and prevent disease progression.
Pertuzumab works by binding to the HER2 receptor on cancer cells, blocking its dimerization with other HER family receptors, which interrupts critical signaling pathways responsible for cell proliferation. This dual HER2 blockade enhances the effectiveness of anti-cancer therapy and improves survival outcomes.
Each vial of Perjeta contains 420mg of Pertuzumab in 14ml solution, administered via intravenous (IV) infusion under the supervision of a qualified oncologist.
Perjeta is indicated for:
First-line treatment of HER2-positive metastatic breast cancer.
Neoadjuvant (pre-surgery) therapy for early-stage HER2-positive breast cancer.
Treatment involves an initial loading dose followed by maintenance doses every 3 weeks, aligned with chemotherapy cycles. Infusions are given in a controlled clinical setting with patient monitoring.
Common side effects include diarrhea, alopecia (hair loss), neutropenia, nausea, fatigue, and rash. Cardiomyopathy and infusion-related reactions, though rare, require immediate medical attention.
Store Perjeta vials in a refrigerator at 2°C to 8°C, protected from light. Do not freeze or shake.
Perjeta 420mg Injection (Pertuzumab)
Perjeta 420mg Injection is a recombinant humanized monoclonal antibody that targets the HER2 receptor, a key driver of cancer cell growth in HER2-positive breast cancer. This targeted therapy is primarily used in combination with trastuzumab (Herceptin) and chemotherapy as a first-line treatment for patients with metastatic or early-stage HER2-positive breast cancer.
Mechanism of Action
Pertuzumab binds to a unique site on the HER2 receptor, preventing its dimerization with other HER receptors—particularly HER3. As a result, the drug inhibits downstream signaling pathways responsible for tumor cell growth and survival. This mechanism enhances the effectiveness of trastuzumab, offering a more complete HER2 blockade and improved clinical outcomes.
Approved Indications
- First-line therapy for HER2-positive metastatic breast cancer
- Neoadjuvant treatment for HER2-positive early breast cancer with a high risk of recurrence
Dosage and Administration
The typical regimen starts with a loading dose of 840mg, followed by maintenance doses of 420mg every three weeks via intravenous infusion. The total duration of therapy depends on patient response and disease progression. It is crucial to monitor cardiac function periodically, as HER2-targeted therapies can increase the risk of cardiotoxicity.
Possible Side Effects
Common adverse effects include:
- Diarrhea
- Nausea
- Alopecia (hair loss)
- Fatigue
- Neutropenia
- Rash
Although rare, serious complications such as heart failure or hypersensitivity reactions may occur. Immediate medical attention is necessary if these symptoms appear.
Infusion Monitoring
Infusion-related reactions are typically mild and can be managed with premedication and close observation during and after the infusion session.
Storage Instructions
Keep Perjeta vials refrigerated between 2°C and 8°C. Do not freeze or expose the medication to light.
Explore More
For additional HER2-targeted therapies and cancer care solutions, visit our
Medicine Category. You can also browse a wide selection of pharmaceutical products at our
online pharmacy shop.
Related products
